AD/PD 2022: Eisai looks to differentiate lecanemab from the crowd - Clinical Trials Arena

Retrieved on: 2022-03-21 11:17:26

Tags for this article:

Click the tags to see associated articles and topics

AD/PD 2022: Eisai looks to differentiate lecanemab from the crowd - Clinical Trials Arena. View article details on hiswai:

Excerpt

Lecanemab's mechanism of action differs from that of other Aβ monoclonal antibodies (mAbs) indicated for Alzheimer's disease.

Article found on: www.clinicaltrialsarena.com